Is there really room for anti-rheumatic drugs in the treatment of COVID-19?

Favalli, E G; Ingegnoli, F; Biggioggero, M; Caporali, R

Favalli, E G; Ingegnoli, F; Biggioggero, M; Caporali, R.

Favalli EG; Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute , Milan, Italy.
Ingegnoli F; Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute , Milan, Italy.
Biggioggero M; Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan , Milan, Italy.
Caporali R; Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute , Milan, Italy.

Scand J Rheumatol ; 49(5): 412-413, 2020 09.

Article in English | MEDLINE | ID: covidwho-684323

Subject(s)

Antirheumatic Agents; Coronavirus Infections; Pandemics; Pneumonia, Viral; Adult; Betacoronavirus; COVID-19; China; Humans; Inpatients; Retrospective Studies; Risk Factors; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antirheumatic Agents / Pandemics Type of study: Observational study / Prognostic study Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: Scand J Rheumatol Year: 2020 Document Type: Article Affiliation country: 03009742.2020.1765413

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google